These 3 ASX healthcare shares have all had their fair share of issues over the past few months.
Investors walked out, and as a result the share prices of CSL Ltd (ASX: CSL), Sigma Healthcare Ltd (ASX: SIG) and Sonic Healthcare Ltd have been under pressure.
But it's not all pain and pills. Brokers see potential 15-35% upside for these quality ASX healthcare shares.
Let's go and check them out.
Image source: Getty Images
CSL Ltd (ASX: CSL)
CSL, the $85 billion healthcare heavyweight, has had a proper clanger of a year. The share price slid as investors panicked over high plasma collection costs, sluggish margin recovery and patchy vaccine demand.
For a stock once treated like a superannuation heirloom — buy it, forget it, brag about it — the stumble has been confronting.
But here's the plot twist. This ASX healthcare share hasn't forgotten how to grow. Plasma volumes are ticking up, cost pressures are easing and management insists margins can recover with a bit of patience and fewer market tantrums.
This year doesn't need to be heroic. It just needs to be less disappointing for sentiment to flip. Yes, execution matters and margins must recover.
Still, analysts remain bullish, tipping an average 12-month price target of $232.15. That points to a 34%, suggesting the market may have overdone the exodus.
Sigma Healthcare Ltd (ASX: SIG)
Sigma Healthcare hasn't been feeling the love lately — and it's not hard to see why.
First up: merger mayhem. The Chemist Warehouse tie-up sent integration and transaction costs through the roof, smashing near-term profits and rattling investors.
Then there's the hangover from past mistakes. A bungled ERP rollout a few years back snarled supply chains, drove pharmacies into competitors' arms, and bruised the credibility of the ASX healthcare share.
But it's not all bad news. The Chemist Warehouse merger supercharges Sigma's scale, plugging wholesale, distribution and retail into one powerful machine. If the synergies land, earnings could follow.
Tailwinds help too. Australia's ageing population and steady demand for health products keep the long-term story intact.
Analysts see strong scale, improved EBITDA and a growing network which give the ASX healthcare share defensive cash flows and growth runway. A rare thing in healthcare retail.
Brokers predict 12-month average price targets of around $3.30, which implies a potential gain of almost 15% above current levels of $2.90.
Sonic Healthcare Ltd (ASX: SHL)
The 7th largest ASX healthcare share has had a rollercoaster run. Investors sulked after COVID testing faded and earnings guidance was modest, but that's exactly why the value hunters might sniff opportunity.
Expectations are now realistic, maybe even a little too low. Some fair-value models suggest Sonic Healthcare could be 30–40 % undervalued relative to the current price, implying a fair value above $30+ if growth plays out.
The stock currently draws a mix of hold and buy views, with price targets back above recent levels and potential recovery from recent acquisitions and synergy boosts.
Weakness? Margins still feel the hangover from lower testing demand and mixed sentiment from brokers, so Sonic Healthcare isn't a shiny growth rocket. The ASX healthcare share is more a steady-eddy play.
Bell Potter has assigned a buy rating and a $33.30 price target. Based on the share price of $23.03 at the time of writing, this implies a potential upside of 32% for investors over the next 12 months.
Bell Potter is on the bullish side, as the average 12-month target price is $26.73. However, that still points to 18% upside. It could bring the total earnings in 2026, including a dividend yield of 5.2%, to well over 20%.
